Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, et al.
Blood (2020) Vol. 136, Iss. 10, pp. 1134-1143
Open Access | Times Cited: 291

Showing 1-25 of 291 citing articles:

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu, Irit Avivi, Anat Aharon, et al.
Blood (2021) Vol. 137, Iss. 23, pp. 3165-3173
Open Access | Times Cited: 602
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira, Inna Y. Gong, Thomas A. Fox, et al.
Blood (2020) Vol. 136, Iss. 25, pp. 2881-2892
Open Access | Times Cited: 584
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti, Chiara Cattaneo, Luca Arcaini, et al.
The Lancet Haematology (2020) Vol. 7, Iss. 10, pp. e737-e745
Open Access | Times Cited: 522
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Erin Bange, Nicholas Han, Paul Wileyto, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1280-1289
Open Access | Times Cited: 444
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah, et al.
JAMA Oncology (2021) Vol. 7, Iss. 8, pp. 1167-1167
Open Access | Times Cited: 171
Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
Marina Treskova, Laura Haas, Sarah Reda, et al.
BMC Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 151
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
Lindsey E. Roeker, David A. Knorr, Meghan C. Thompson, et al.
Leukemia (2021) Vol. 35, Iss. 9, pp. 2703-2705
Open Access | Times Cited: 147
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
Helen Parry, Graham McIlroy, Rachel Bruton, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 7
Open Access | Times Cited: 115
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
Yair Herishanu, Galia Rahav, Shai Levi, et al.
Blood (2021) Vol. 139, Iss. 5, pp. 678-685
Open Access | Times Cited: 110
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Jason D. Goldman, Philip C. Robinson, Thomas S. Uldrick, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002630-e002630
Open Access | Times Cited: 105
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer
Emma G Khoury, Sarah J Nevitt, William Rohde Madsen, et al.
JAMA Network Open (2022) Vol. 5, Iss. 5, pp. e2210880-e2210880
Open Access | Times Cited: 74
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Thomas Müller, Yu Gao, Jinghua Wu, et al.
Cell Host & Microbe (2024) Vol. 32, Iss. 2, pp. 156-161.e3
Open Access | Times Cited: 23
COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges
Anup S. Pathania, Philip Prathipati, Abdul Bakrudeen Ali Ahmed, et al.
Theranostics (2020) Vol. 11, Iss. 2, pp. 731-753
Open Access | Times Cited: 113
Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky, Nicole Lamanna
Hematology (2020) Vol. 2020, Iss. 1, pp. 336-345
Open Access | Times Cited: 113
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Ohad Benjamini, Lior Rokach, Gilad Itchaki, et al.
Haematologica (2021) Vol. 107, Iss. 3, pp. 625-634
Open Access | Times Cited: 95
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
Lindsey E. Roeker, David A. Knorr, Melissa S. Pessin, et al.
Leukemia (2020) Vol. 34, Iss. 11, pp. 3047-3049
Open Access | Times Cited: 93
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, et al.
Leukemia (2021) Vol. 35, Iss. 12, pp. 3444-3454
Open Access | Times Cited: 85
The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities
Shatha K. Alyammahi, Shifaa M. Abdin, Dima W. Alhamad, et al.
Infection Genetics and Evolution (2020) Vol. 87, pp. 104647-104647
Open Access | Times Cited: 75
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies
David J. Chung, Gunjan L. Shah, Sean M. Devlin, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 568-576
Open Access | Times Cited: 70
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2014-2034
Open Access | Times Cited: 70
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, et al.
Blood (2021) Vol. 138, Iss. 18, pp. 1768-1773
Open Access | Times Cited: 67
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
Son Tran, Tony H. Truong, Aru Narendran
European Journal of Cancer (2021) Vol. 159, pp. 259-274
Open Access | Times Cited: 65
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study
Isabel Regalado‐Artamendi, Ana Jiménez Ubieto, José‐Ángel Hernández‐Rivas, et al.
HemaSphere (2021) Vol. 5, Iss. 3, pp. e538-e538
Open Access | Times Cited: 63
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
Francesco Passamonti, Alessandra Romano, Marco Salvini, et al.
British Journal of Haematology (2021) Vol. 195, Iss. 3, pp. 371-377
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top